MRSN — Mersana Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $356.63m
- $172.98m
- $36.86m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -28.2 | -88 | -170 | -204 | -172 |
Depreciation | |||||
Non-Cash Items | 4.75 | 7.23 | 19.1 | 20.8 | 17.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -45.5 | 5.11 | 10.1 | 133 | -16 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -67.7 | -74.7 | -140 | -49.4 | -169 |
Capital Expenditures | -0.605 | -0.473 | -0.648 | -2.2 | -2.17 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -26.7 | 37.5 | 0 | -151 | 122 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -27.3 | 37 | -0.648 | -153 | 120 |
Financing Cash Flow Items | — | — | -0.259 | 0 | -0.15 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 97.7 | 230 | 63.6 | 153 | 94.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.67 | 193 | -77 | -49.1 | 45.7 |